Chemoradiotherapy

Delaying surgery appeared associated with worse OS and DFS among patients with locally advanced rectal cancer and poor tumor pathologic response to neoadjuvant chemoradiotherapy, according to study results published in JAMA Surgery.

Patients with isocitrate dehydrogenase wild-type glioblastoma who used levetiracetam for the duration of chemoradiation may have a higher overall survival rate, according to an observational, retrospective cohort study in Neurology.

In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, discussed the “practice-changing” results from the OUTBACK trial.

Sonam Puri, MD, spoke with Healio about updated findings from the PACIFIC trial presented at this year’s virtual annual ASCO meeting.

Giving durvalumab to patients with stage III non-small cell lung cancer after chemoradiation reduced the risk for death and disease progression, according to data 5 years after initiation of the PACIFIC trial.

A 2-year update on Checkmate9LA suggested that combining nivolumab with ipilimumab and two cycles of chemoradiation may be better than four cycles of chemoradiation alone, according to a speaker at the virtual 2021 ASCO Annual Meeting.

Use of pembrolizumab alongside chemoradiation therapy induces antitumor activity in previously untreated unresectable, locally advanced stage III non-small cell lung cancer, according to a presenter at the virtual 2021 ASCO Annual Meeting.

In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, discussed the OUTBACK trial presented at the ASCO Annual Meeting.

Researchers confirmed the long-term oncological safety of laparoscopic surgery was comparable to the long-term safety of open surgery in patients with rectal cancer, according to The Lancet Gastroenterology and Hepatology.

Weekly cisplatin appeared noninferior to an every-3-weeks dose as part of chemoradiotherapy regimen for certain patients with head and neck squamous cell carcinoma, according to study results presented during the ASCO20 Virtual Scientific Program.